Seres Therapeutics, Inc.
General ticker "MCRB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $124.9M (TTM average)
Seres Therapeutics, Inc. follows the US Stock Market performance with the rate: 33.4%.
Estimated limits based on current volatility of 1.7%: low 8.92$, high 9.41$
Factors to consider:
- Earnings expected soon, date: 2026-03-12 bmo
- Total employees count: 103 (-55.8%) as of 2024
- Company does not operate outside US (retrieved using AI)
- Top business risk factors: Insufficient funding, Limited pipeline diversity, Third-party risks, Regulatory and compliance, Geopolitical risks
- Price in estimated range
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [10.31$, 28.12$]
- 2025-12-31 to 2026-12-31 estimated range: [8.06$, 22.42$]
Short-term MCRB quotes
Long-term MCRB plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $179.91MM | $195.10MM | $121.31MM |
| Operating Income | $-179.91MM | $-195.10MM | $-121.31MM |
| Non-Operating Income | $-3.67MM | $4.97MM | $-4.46MM |
| Interest Expense | $6.02MM | $2.47MM | $0.00MM |
| R&D Expense | $109.65MM | $117.60MM | $64.60MM |
| Income(Loss) | $-183.58MM | $-190.13MM | $-125.77MM |
| Other Income(Loss) | $-66.58MM | $76.41MM | $125.91MM |
| Profit(Loss)* | $-316.73MM | $-37.32MM | $126.04MM |
| Stockholders Equity | $10.78MM | $-44.86MM | $13.78MM |
| Inventory | $0.00MM | $29.65MM | $0.00MM |
| Assets | $348.78MM | $358.60MM | $139.81MM |
| Operating Cash Flow | $-228.82MM | $-117.35MM | $-148.61MM |
| Capital expenditure | $9.82MM | $7.97MM | $0.38MM |
| Investing Cash Flow | $82.43MM | $10.58MM | $142.29MM |
| Financing Cash Flow | $129.60MM | $71.70MM | $-90.37MM |
| Earnings Per Share** | $-58.61 | $-5.83 | $16.22 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.